Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence

Stefano Cianci, Carlo Ronsini, Giuseppe Vizzielli, Alessandro Tropea, Antonio Biondi, Giovanni Scambia, Anna Fagotti

Research output: Contribution to journalArticle

Abstract

Secondary and tertiary cytoreductive surgery was associated with improved overall survival in platinum-sensitive recurrent ovarian cancer (ROC). Hyperthermic intraoperative intra-peritoneal chemotherapy (HIPEC) is considered an attractive method in the treatment of ROC to deliver chemotherapy with enhanced effect directly at the tumor site. However, another deserving aspect is the feasibility and the oncologic role of HIPEC repetition. Twelve patients affected by secondary ovarian cancer recurrence previously submitted to cytoreduction followed by HIPEC were enrolled for the present study to receive tertiary cytoreduction followed by HIPEC repetition. The median operative time, including time for HIPEC procedure, was 360 min (range 240-540). Average EBL was 325 ml (from 100 to 500 ml). The median hospital stay was of 5 days, from 4 to 10. Low-grade post operatory complications occurred in 2 patients (16.6%) and high-grade complication in 1 case (8.3%). Our study report encouraging data about safety of HIPEC repetition in ovarian cancer treatment.

Original languageEnglish
JournalUpdates in Surgery
DOIs
Publication statusE-pub ahead of print - Nov 8 2018

Fingerprint

Ovarian Neoplasms
Recurrence
Drug Therapy
Operative Time
Platinum
Length of Stay
Safety
Survival
Therapeutics
Neoplasms

Cite this

Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence. / Cianci, Stefano; Ronsini, Carlo; Vizzielli, Giuseppe; Tropea, Alessandro; Biondi, Antonio; Scambia, Giovanni; Fagotti, Anna.

In: Updates in Surgery, 08.11.2018.

Research output: Contribution to journalArticle

@article{1b62a8c64a2b4746af261f5c5020502e,
title = "Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence",
abstract = "Secondary and tertiary cytoreductive surgery was associated with improved overall survival in platinum-sensitive recurrent ovarian cancer (ROC). Hyperthermic intraoperative intra-peritoneal chemotherapy (HIPEC) is considered an attractive method in the treatment of ROC to deliver chemotherapy with enhanced effect directly at the tumor site. However, another deserving aspect is the feasibility and the oncologic role of HIPEC repetition. Twelve patients affected by secondary ovarian cancer recurrence previously submitted to cytoreduction followed by HIPEC were enrolled for the present study to receive tertiary cytoreduction followed by HIPEC repetition. The median operative time, including time for HIPEC procedure, was 360 min (range 240-540). Average EBL was 325 ml (from 100 to 500 ml). The median hospital stay was of 5 days, from 4 to 10. Low-grade post operatory complications occurred in 2 patients (16.6{\%}) and high-grade complication in 1 case (8.3{\%}). Our study report encouraging data about safety of HIPEC repetition in ovarian cancer treatment.",
author = "Stefano Cianci and Carlo Ronsini and Giuseppe Vizzielli and Alessandro Tropea and Antonio Biondi and Giovanni Scambia and Anna Fagotti",
year = "2018",
month = "11",
day = "8",
doi = "10.1007/s13304-018-0600-y",
language = "English",
journal = "Updates in Surgery",
issn = "2038-131X",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence

AU - Cianci, Stefano

AU - Ronsini, Carlo

AU - Vizzielli, Giuseppe

AU - Tropea, Alessandro

AU - Biondi, Antonio

AU - Scambia, Giovanni

AU - Fagotti, Anna

PY - 2018/11/8

Y1 - 2018/11/8

N2 - Secondary and tertiary cytoreductive surgery was associated with improved overall survival in platinum-sensitive recurrent ovarian cancer (ROC). Hyperthermic intraoperative intra-peritoneal chemotherapy (HIPEC) is considered an attractive method in the treatment of ROC to deliver chemotherapy with enhanced effect directly at the tumor site. However, another deserving aspect is the feasibility and the oncologic role of HIPEC repetition. Twelve patients affected by secondary ovarian cancer recurrence previously submitted to cytoreduction followed by HIPEC were enrolled for the present study to receive tertiary cytoreduction followed by HIPEC repetition. The median operative time, including time for HIPEC procedure, was 360 min (range 240-540). Average EBL was 325 ml (from 100 to 500 ml). The median hospital stay was of 5 days, from 4 to 10. Low-grade post operatory complications occurred in 2 patients (16.6%) and high-grade complication in 1 case (8.3%). Our study report encouraging data about safety of HIPEC repetition in ovarian cancer treatment.

AB - Secondary and tertiary cytoreductive surgery was associated with improved overall survival in platinum-sensitive recurrent ovarian cancer (ROC). Hyperthermic intraoperative intra-peritoneal chemotherapy (HIPEC) is considered an attractive method in the treatment of ROC to deliver chemotherapy with enhanced effect directly at the tumor site. However, another deserving aspect is the feasibility and the oncologic role of HIPEC repetition. Twelve patients affected by secondary ovarian cancer recurrence previously submitted to cytoreduction followed by HIPEC were enrolled for the present study to receive tertiary cytoreduction followed by HIPEC repetition. The median operative time, including time for HIPEC procedure, was 360 min (range 240-540). Average EBL was 325 ml (from 100 to 500 ml). The median hospital stay was of 5 days, from 4 to 10. Low-grade post operatory complications occurred in 2 patients (16.6%) and high-grade complication in 1 case (8.3%). Our study report encouraging data about safety of HIPEC repetition in ovarian cancer treatment.

U2 - 10.1007/s13304-018-0600-y

DO - 10.1007/s13304-018-0600-y

M3 - Article

C2 - 30406932

JO - Updates in Surgery

JF - Updates in Surgery

SN - 2038-131X

ER -